Seeking Alpha
14 Aug 2026, 06:15 UTC · 1h ago
Ultragenyx: Undervalued Ahead Of Two FDA Decisions
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
14 Aug 2026, 06:15 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA is expected to issue a decision on DTX401 on August 23. — Binary regulatory events for pipeline drugs are primary drivers of short-term stock volatility and valuation.
+0.60The FDA is expected to issue a decision on UX111 on September 19. — A second near-term regulatory decision provides another significant catalyst for price movement.
+0.50Ultragenyx has a probability-weighted fair value of approximately $32 per share compared to a current price of $27. — Indicates a potential upside of ~18% based on the analyst's valuation of the drug approval odds.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is rated as a soft Buy with a fair value estimate significantly higher than its current share price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
